Consistent and significant inhibition of human immunodeficiency virus type 1 envelope-mediated membrane fusion by β-chemokines (RANTES) in primary human macrophages

Journal of Infectious Diseases

Volumn 182, Issue 1, 2000, Pages 68-78

  Stantchev, Tzanko S ^a   Broder, Christopher C ^a  

^a Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; RANTES;

ARTICLE; CELL DIFFERENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE ACTIVATION; MEMBRANE FUSION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BLOCKING; RECEPTOR DOWN REGULATION; VIRUS CULTURE; VIRUS INHIBITION; VIRUS REPLICATION;

CHEMOKINES, CC; CHEMOKINES, CXC; DRUG INTERACTIONS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; MACROPHAGES; MEMBRANE FUSION; RANTES;

EID: 0033914446     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315700     Document Type: Article

References (100)

1. 1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17:657-700.
2. 2. Broder CC, Jones-Trower A. Coreceptor use by primate lentiviruses. In: Korber B, Foley B, Leitner T, et al., eds. Human retroviruses and AIDS. Vol. 3. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1999:20-45.
3. 3. Garzino-Demo A, DeVico AL, Cocchi F, Gallo RC. Beta-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998; 14(suppl 2):S177-84.
4. 4. Trkola A, Paxton WA, Monard SP, et al. Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines. J Virol 1998; 72:396-404.
5. +, T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with non-syncytium-inducing HIV-1 in vitro. J Virol 1998; 72:876-81.
6. 6. Kelly MD, Naif HM, Adams SL, Cunningham AL, Lloyd AR. Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages. J Immunol 1998; 160:3091-5.
7. 7. Simmons G, Clapham PR, Picard L, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997; 276:276-9.
8. 8. Schols D, Struyf S, Van Damme J, Este JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186:1383-8.
9. 9. Doranz BJ, Grovit-Ferbas K, Sharron MP, et al. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997; 186:1395-400.
10. 10. Murakami T, Nakajima T, Koyanagi Y, et al. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997; 186:1389-93.
11. + T cells. Science 1995; 270: 1811-5.
12. 12. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3:1259-65.
13. + T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci USA 1996; 93:14076-81.
14. 14. Wagner L, Yang OO, Garcia-Zepeda EA, et al. Beta-chemokines are released from HIV-1 specific cytolytic T-cell granules complexed to proteoglycans. Nature 1998; 391:908-11.
15. 15. Mackewicz CE, Barker E, Levy JA. Role of beta-chemokines in suppressing HIV replication. Science 1996; 274:1393-5.
16. 16. Verani A, Scarlatti G, Comar M, et al. C-C chemokines released by lipopolysaccharide (LPS)-stimulated human macrophages suppress HIV-1 infection in both macrophages and T cells. J Exp Med 1997; 185:805-16.
17. 17. Ayehunie S, Garcia-Zepeda EA, Hoxie JA, et al. Human immunodeficiency virus-1 entry into purified blood dendritic cells through CC and CXC chemokine coreceptors. Blood 1997; 90:1379-86.
18. 18. Granelli-Piperno A, Moser B, Pope M, et al. Efficient interaction of HIV-1 with purified dendritic cells via multiple chemokine coreceptors. J Exp Med 1996; 184:2433-8.
19. 19. Oravecz T, Pall M, Wang J, Roderiquez G, Ditto M, Norcross MA. Regulation of anti-HIV-1 activity of RANTES by heparan sulfate proteoglycans. J Immunol 1997; 159:4587-92.
20. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73.
21. 21. Ghorpade A, Xia MQ, Hyman BT, et al. Role of the beta-chemokine receptors CCR3 and CCR5 in human immunodeficiency virus type 1 infection of monocytes and microglia. J Virol 1998; 72:3351-61.
22. + T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1 alpha, and MIP-1 beta, suppress HIV-1 replication in monocyte/macrophages. Proc Natl Acad Sci USA 1996; 93:15341-5.
23. 23. Schmidtmayerova H, Sherry B, Bukrinsky M. Chemokines and HIV replication. Nature 1996; 382:767.
24. 24. Ylisastigui L, Amzazi S, Bakri Y, et al. Effect of RANTES on the infection of monocyte-derived primary macrophages by human immunodeficiency virus type 1 and type 2. Biomed Pharmacother 1998; 52:447-53.
25. 25. Trkola A, Gordon C, Matthews J, et al. The CC-chemokine RANTES increases the attachment of human immunodeficiency virus type 1 to target cells via glycosaminoglycans and also activates a signal transduction pathway that enhances viral infectivity. J Virol 1999; 73:6370-9.
26. 26. Gordon CJ, Muesing MA, Proudfoot AE, Power CA, Moore JP, Trkola A. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J Virol 1999; 73:684-94.
27. 27. Lee B, Montaner LJ. Chemokine immunobiology in HIV-1 pathogenesis. J Leukoc Biol 1999; 65:552-65.
28. 28. Cohen O, Weissman D, Fauci AS. The Immunopathogenesis of HIV Infection. In: Paul WE, ed. Fundamental Immunology. Philadelphia: Lippincott-Raven, 1999:1511-34.
29. 29. Saha K, Volsky DJ. Are beta-chemokines innocent bystanders in HIV type 1 disease progression? AIDS Res Hum Retroviruses 1998; 14:1-2.
30. 30. Clerici M, Balotta C, Trabattoni D, et al. Chemokine production in HIV-seropositive long-term asymptomatic individuals. Aids 1996; 10:1432-3.
31. 31. Mackewicz CE, Barker E, Greco G, Reyes-Teran G, Levy JA. Do beta-chemokines have clinical relevance in HIV infection? J Clin Invest 1997; 100:921-30.
32. 32. Scala E, D'Offizi G, Rosso R, et al. C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J Immunol 1997; 158:4485-92.
33. + cells in HIV infection produce macrophage inflammatory protein-1 alpha and RANTES: a comparative study in long-term survivors and progressor patients. Immunol Lett 1996; 53:105-8.
34. + lymphocytes are not related to beta-chemokine production. AIDS Res Hum Retroviruses 1998; 14:1407-11.
35. 35. Ullum H, Cozzi Lepri A, Victor J, et al. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998; 177:331-6.
36. 36. Garzino-Demo A, Moss RB, Margolick JB, et al. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc Natl Acad Sci USA 1999; 96:11986-91.
37. 37. Kumar D, Parato K, Kumar A, Sun E, Cameron DW, Angel JB. Sustained suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1alpha and MIP-1beta. AIDS Res Hum Retroviruses 1999; 15:1073-7.
38. 38. Coffey MJ, Woffendin C, Phare SM, Strieter RM, Markovitz DM. RANTES inhibits HIV-1 replication in human peripheral blood monocytes and alveolar macrophages. Am J Physiol 1997; 272:L1025-9.
39. + T cells. AIDS Res Hum Retroviruses 1999; 15:1453-60.
40. 40. Robbins PA, Roderiquez GL, Peden KW, Norcross MA. Human immunodeficiency virus type 1 infection of antigen-specific CD4 cytotoxic T lymphocytes. AIDS Res Hum Retroviruses 1998; 14:1397-406.
41. 41. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280:67-71.
42. 42. Wodarz D, Lloyd AL, Jansen VA, Nowak MA. Dynamics of macrophage and T cell infection by HIV. J Theor Biol 1999; 196:101-13.
43. 43. Capobianchi MR, Abbate I, Antonelli G, Turriziani O, Dolei A, Dianzani F. Inhibition of HIV type 1 BaL replication by MIP-1alpha, MIP-1beta, and RANTES in macrophages. AIDS Res Hum Retroviruses 1998; 14: 233-40.
44. + cells from HIV-infected individuals can suppress productive infection of macrophages independent of beta-chemokines. Proc Natl Acad Sci USA 1998; 95:1725-9.
45. 45. Roulston A, Lin R, Beauparlant P, Wainberg MA, Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev 1995; 59:481-505.
46. + T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 1998; 395:189-94.
47. 47. Broder CC, Kennedy PE, Michaels F, Berger EA. Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors. Gene 1994; 142:167-74.
48. 48. Lazdins JK, Woods-Cook K, Walker M, Alteri E. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Res Hum Retroviruses 1990; 6:1157-61.
49. + T-cell lines vs. primary macrophages. Proc Natl Acad Sci USA 1995; 92:9004-8.
50. 50. Fuerst TR, Niles EG, Studier FW, Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 1986; 83:8122-6.
51. 51. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol 1996; 70:5487-94.
52. 52. Berger EA, Nussbaum O, Broder CC. HIV envelope glycoproteins/CD4 interactions: studies using recombinant vaccinia vectors. In: Karn J, ed. HIV: a practical approach. Vol. 2. Oxford, UK: Oxford University Press, 1995:123-45.
53. 53. Nussbaum O, Broder CC, Berger EA. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J Virol 1994; 68:5411-22.
54. 54. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995; 206:935-44.
55. 55. O'Brien WA, Koyanagi Y, Namazie A, et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 1990; 348:69-73.
56. 56. Westervelt P, Gendelman HE, Ratner L. Identification of a determinant within the human immunodeficiency virus type 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci USA 1991; 88:3097-101.
57. 57. Bagwell B. A journey through flow cytometric immunofluorescence analyses: finding accurate and robust algorithms that estimate positive fraction distributions. Clin Immunol Newslett 1996; 16:33-8.
58. 58. Deng X, Ueda H, Su SB, et al. A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 1999; 94:1165-73.
59. 59. Grimm MC, Ben-Baruch A, Taub DD, et al. Opiates transdeactivate chemokine receptors: delta and mu opiate receptor-mediated heterologous desensitization. J Exp Med 1998; 188:317-25.
60. 60. Campbell JJ, Foxman EF, Butcher EC. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur J Immunol 1997; 27:2571-8.
61. 61. Marechal V, Arenzana-Seisdedos F, Heard JM, Schwartz O. Opposite effects of SDF-1 on human immunodeficiency virus type 1 replication. J Virol 1999; 73:3608-15.
62. 62. Dolei A, Biolchini A, Serra C, Curreli S, Gomes E, Dianzani F. Increased replication of T-cell-tropic HIV strains and CXC-chemokine receptor-4 induction in T cells treated with macrophage inflammatory protein (MIP)-1alpha, MIP-1beta and RANTES beta-chemokines. Aids 1998; 12:183-90.
63. +) T cells: role of signal transduction. Proc Natl Acad Sci USA 1998; 95:11880-5.
64. 64. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382:829-33.
65. 65. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382:833-5.
66. 66. Jansson M, Popovic M, Karlsson A, et al. Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. Proc Natl Acad Sci USA 1996; 93:15382-7.
67. 67. Yi Y, Isaacs SN, Williams DA, et al. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism. J Virol 1999; 73:7117-25.
68. 68. Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. J Virol 1998; 72:4633-42.
69. 69. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG. CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72:772-7.
70. 70. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996; 384:529-34.
71. 71. Worgall S, Connor R, Kaner RJ, et al. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. J Virol 1999; 73:5865-74.
72. 72. Herbein G, Doyle AG, Montaner LJ, Gordon S. Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1 beta. Clin Exp Immunol 1995; 102:430-7.
73. 73. Eugen-Olsen J, Afzelius P, Andresen L, et al. Serotonin modulates immune function in T cells from HIV-seropositive subjects. Clin Immunol Immunopathol 1997; 84:115-21.
74. 74. Dumais N, Barbeau B, Olivier M, Tremblay MJ. Prostaglandin E2 up-regulates HIV-1 long terminal repeat driven gene activity in T cells via NF-kappaB dependent and independent signaling pathways. J Biol Chem 1998; 273:27306-14.
75. 75. Chowdhury MI, Koyanagi Y, Horiuchi S, et al. cAMP stimulates human immunodeficiency virus (HIV-1) from latently infected cells of monocyte-macrophage lineage: synergism with TNF-alpha. Virology 1993; 194: 345-9.
76. 76. Rabbi MF, al-Harthi L, Saifuddin M, Roebuck KA. The cAMP-dependent protein kinase A and protein kinase C-beta pathways synergistically interact to activate HIV-1 transcription in latently infected cells of monocyte/macrophage lineage. Virology 1998; 245:257-69.
77. 77. Guntermann C, Murphy BJ, Zheng R, Qureshi A, Eagles PA, Nye KE. Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein coupled signalling and mediates cAMP downregulation. Biochem Biophys Res Commun 1999; 256:429-35.
78. 78. Murphy PM. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev 1996; 7:47-64.
79. 79. Nagira M, Sato A, Miki S, Imai T, Yoshie O. Enhanced HIV-1 replication by chemokines constitutively expressed in secondary lymphoid tissues. Virology 1999; 264:422-6.
80. 80. Sanchez-Madrid F, del Pozo MA. Leukocyte polarization in cell migration and immune interactions. EMBO J 1999; 18:501-11.
81. 81. Thivierge M, Le Gouill C, Tremblay MJ, Stankova J, Rola-Pleszczynski M. Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 1998; 92:40-5.
82. 82. del Pozo MA, Sanchez-Mateos P, Nieto M, Sanchez-Madrid F. Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway. J Cell Biol 1995; 131:495-508.
83. 83. Barcova M, Speth C, Kacani L, Uberall F, Stoiber H, Dierich MP. Involvement of adenylate cyclase and p70(S6)-kinase activation in IL-10 up-regulation in human monocytes by gp41 envelope protein of human immunodeficiency virus type 1. Pflugers Arch 1999; 437:538-46.
84. 84. Schlessinger J, Lax I, Lemmon M. Regulation of growth factor activation by proteoglycans: what is the role of the low affinity receptors? Cell 1995; 83:357-60.
85. 85. Tanaka Y, Kimata K, Adams DH, Eto S. Modulation of cytokine function by heparan sulfate proteoglycans: sophisticated models for the regulation of cellular responses to cytokines. Proc Assoc Am Physicians 1998; 110: 118-25.
86. 86. Amzazi S, Ylisastigui L, Bakri Y, et al. The inhibitory effect of RANTES on the infection of primary macrophages by R5 human immunodeficiency virus type-1 depends on the macrophage activation state. Virology 1998; 252:96-105.
87. 87. Jackson DG. Human leucocyte heparan sulphate proteoglycans and their roles in inflammation. Biochem Soc Trans 1997; 25:220-4.
88. 88. Jiang Y, Jolly PE. Effect of beta-chemokines on human immunodeficiency virus type 1 replication, binding, uncoating, and CCR5 receptor expression in human monocyte-derived macrophages. J Hum Virol 1999; 2: 123-32.
89. 89. Lee B, Sharron M, Montaner LJ, Weissman D, Doms RW. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96:5215-20.
90. 90. Vicenzi E, Biswas P, Mengozzi M, Poli G. Role of pro-inflammatory cytokines and beta-chemokines in controlling HIV replication. J Leukoc Biol 1997; 62:34-40.
91. + T cell supernatants of HIV type 1-infected individuals have opposite effects on long terminal repeat-mediated transcription in T cells and monocytes. AIDS Res Hum Retroviruses 1997; 13:71-7.
92. + T cell soluble factors. Clin Exp Immunol 1998; 114:87-93.
93. 93. Paxton WA, Koup RA. Mechanisms of resistance to HIV infection. Springer Semin Immunopathol 1997; 18:323-40.
94. + lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998; 244:66-73.
95. 95. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95:3857-61.
96. +) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997; 186: 455-60.
97. 97. Polo S, Veglia F, Malnati MS, et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. Aids 1999; 13:447-54.
98. 98. Zanussi S, D'Andrea M, Simonelli C, Tirelli U, De Paoli P. Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progressor patients. AIDS 1996; 10:1431-2.
99. 99. Kim JJ, Nottingham LK, Sin JI, et al. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102:1112-24.
100. 100. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19:568-74.